Search results
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 2 days agoA deputy was calling with good news: The company’s new, experimental drug tirzepatide not only cut...
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It
Motley Fool via Yahoo Finance· 10 hours agoIt was a phase-one trial but an encouraging one nonetheless. AstraZeneca has shown interest in the...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Motley Fool via Yahoo Finance· 11 hours agoAlpine's porvetacicept should advance into phase 3 testing for treating the rare kidney disease IgA...
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity ...
Motley Fool via Yahoo Finance· 2 days ago/Mounjaro could achieve greater weight loss. This efficacy advantage could enable Lilly's weight-...
Guidelines outline nutrition requirements for those on Ozempic, Wegovy, Zepbound
UPI· 4 days agoFolks using a weight-loss drugs like Ozempic, Wegovy or Zepbound still have nutritional requirements...
Experimental GLP-1 Med Might Be Breakthrough Against Fatty Liver Disease | FOX 28 Spokane
FOX 28 Spokane· 5 days agoAn experimental ‘supercharged’ form of popular GLP-1 weight-loss meds could help ease fatty liver...
Merck pursuing next-generation opportunities in cardiometabolic drugs
Reuters via AOL· 4 days ago(Reuters) -Merck is focused on second- and third-generation opportunities in the cardiometabolic...
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time...
Motley Fool via Yahoo Finance· 5 days agoThe stock market is responding to a positive readout for an experimental weight-management drug the...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 3 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Skye Bioscience to stop eye disease drug development after failing mid-stage study
Reuters via AOL· 5 days agoIn the 56-subject study, the eye drop, SBI-100, failed to significantly lower eye pressure in patients with primary open-angle glaucoma when compared with the placebo, the company said. In this ...